Molecular classification of breast carcinoma

Diagnostic Histopathology

Volumn 18, Issue 3, 2012, Pages 97-103

  Alizart, Michelle ^a   Saunus, Jodi ^b   Cummings, Margaret ^a   Lakhani, Sunil R ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Breast cancer; Breast cancer special types; Gene expression profiling; Molecular classification; Prognostic signatures; Therapeutic targets

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CLINICAL PRACTICE; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MULTIGENE FAMILY; PATIENT CARE; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; RECURRENCE FREE SURVIVAL; REPRODUCIBILITY; TUMOR SUPPRESSOR GENE;

EID: 84857112744     PISSN: 17562317     EISSN: 18767621     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2011.12.003     Document Type: Article

References (25)

1. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948.
2. Balakrishnan A., Haysom S.A., Ravichandran D. Adjuvant! Online does not significantly influence adjuvant chemotherapy decisions of a breast cancer multidisciplinary team (MDT): a prospective study. Ann Oncol 2011, 22:1461-1462.
3. Reis-Filho J.S., Simpson P.T., Gale T., Lakhani S.R. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract 2005, 201:713-725.
4. Simpson P.T., Reis-Filho J.S., Gale T., Lakhani S.R. Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
5. Perou C.M., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
6. Sorlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
7. Lakhani S.R., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145.
8. Guedj M., et al. A refined molecular taxonomy of breast cancer. Oncogene 2011, 1-11.
9. Hu Z., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
10. Farmer P., et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671.
11. Weigelt B., et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008, 216:141-150.
12. Weigelt B., Kreike B., Reis-Filho J.S. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009, 117:273-280.
13. Tognon C., et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002, 2:367-376.
14. Persson M., Andren Y., Mark J., Horlings H.M., Persson F., Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009, 106:18740-18744.
15. McShane L.M., Radmacher M.D., Freidlin B., Yu R., Li M.C., Simon R. Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 2002, 18:1462-1469.
16. Weigelt B., et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010, 11:339-349.
17. Parker J.S., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
18. Oakman C., Santarpia L., Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 2010, 7:725-732.
19. van't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
20. Fan C., et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569.
21. Reis-Filho J.S., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006, 209:445-453.
22. Reis-Filho J.S., et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006, 12:6652-6662.
23. Turner N., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094.
24. Hennessy B.T., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69:4116-4124.
25. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008, 26:3785-3790.